US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Endo, Inc.

23.59

0.0000

Volume:- -

Turnover:- -

Market Cap:1.80B

PE:- -

High:23.59

Open:23.59

Low:23.59

Close:23.59

52wk High:31.40

52wk Low:19.85

Shares:76.31M

Float Shares:76.16M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:-5.38%

PB:1.60

PE(LYR):- -

Loading ...

Overview Company News Filings

BRIEF-Mallinckrodt Names Christiana Stamoulis As President And Chief Financial Officer

Mallinckrodt Names Christiana Stamoulis as President and Chief Financial Officer

THOMSON REUTERS

Mallinckrodt Plc - Expects Total Company 2025 Net Sales $3.57 Bln-$3.62 Bln - SEC Filing

THOMSON REUTERS

Mallinckrodt Plc - Well Positioned to Move Forward With Par Health Spin-off in Q4

THOMSON REUTERS

Mallinckrodt Plc - Legacy Endo Q2 Revenues of $447.8 Mln - SEC Filing

THOMSON REUTERS

Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting

Endo Inc. to Release Second Quarter 2025 Financial Results

Irish High Court Approves Mallinckrodt and Endo Inc. Merger, Expected to Close in Early August

Endo Inc. Conducted Annual Shareholder Meeting in Malvern

Endo Is Maintained at Buy by BWS Financial

Endo Inc. Completes Sale of International Pharmaceuticals Business to Knight Therapeutics for Up to $105 Million

Press Release: Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader

BRIEF-Mallinckrodt, Endo Announce Planned Leadership Team For Merged Company

Press Release: Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company

Endo Inc. Announces Launch of FDA-Approved ADRENALIN® 8 mg/250 mL Premixed Bag, Expanding Ready-to-Use Epinephrine Line

Press Release: Mallinckrodt and Endo Announce Significant Progress in Proposed Merger

Endo Is Maintained at Buy by BWS Financial

Press Release: Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

BRIEF-Endo To Report First Quarter 2025 Financial Results On May 7, 2025

Endo Initiated at Buy by BWS Financial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NDOI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NDOI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NDOI\",,,,,undefined,":{"symbol":"NDOI","market":"US","secType":"STK","nameCN":"Endo, Inc.","latestPrice":23.59,"timestamp":1771876020000,"preClose":23.59,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":76155500,"shares":76313500,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"02-23 14:47:00 EST Delay","open":23.59,"high":23.59,"low":23.59,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"exchange":"OTCQX","adjPreClose":23.59,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NDOI\",,,,,undefined,":{"symbol":"NDOI","floatShares":76155500,"roa":"-5.38%","roe":"--","lyrEps":0,"shares":76313500,"dividePrice":0,"high":23.59,"amplitude":0,"preClose":23.59,"low":23.59,"week52Low":19.85,"pbRate":"1.60","psRate":"1.04","week52High":31.4,"institutionHeld":0,"latestPrice":23.59,"eps":0,"divideRate":0,"volume":0,"delay":15,"open":23.59,"prevYearClose":23.59,"prevWeekClose":23.59,"prevMonthClose":23.59,"prevQuarterClose":23.59,"fiveDayClose":23.59,"twentyDayClose":23.59,"sixtyDayClose":23.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NDOI\",params:#limit:5,,,undefined,":[{"date":"2025-08-06","symbol":"NDOI","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1754467200000,"name":null,"time":"Pre-Market","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-08-01","symbol":"NDOI","reason":null,"defaultRemindTime":1754055000000,"announcedDate":"2025-07-31","type":"delisting","dateTimestamp":1754020800000},{"date":"2025-05-07","symbol":"NDOI","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1746604800000,"name":null,"time":"Pre-Market","dateTimestamp":1746590400000,"actualEps":null},{"date":"2025-03-13","symbol":"NDOI","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1741852800000,"name":null,"time":"Pre-Market","dateTimestamp":1741838400000,"actualEps":null},{"date":"2024-11-05","symbol":"NDOI","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1730797200000,"name":null,"time":"Pre-Market","dateTimestamp":1730782800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NDOI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NDOI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NDOI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2557370732","title":"BRIEF-Mallinckrodt Names Christiana Stamoulis As President And Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2557370732","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557370732?lang=en_us&edition=fundamental","pubTime":"2025-08-06 21:41","pubTimestamp":1754487712,"startTime":"0","endTime":"0","summary":"BRIEF-Mallinckrodt Names Christiana Stamoulis As President And Chief Financial OfficerAug 6 (Reuters) - MALLINCKRODT NAMES CHRISTIANA STAMOULIS AS PRESIDENT AND CHIEF FINANCIAL OFFICERSource text: ID:nPn2WH3ZTa ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nFWN3TY16O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDOI","BK4007"],"gpt_icon":0},{"id":"2557373106","title":"Mallinckrodt Names Christiana Stamoulis as President and Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2557373106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557373106?lang=en_us&edition=fundamental","pubTime":"2025-08-06 18:45","pubTimestamp":1754477133,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nFWN3TY16O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NDOI","BK4007"],"gpt_icon":0},{"id":"2557378794","title":"Mallinckrodt Plc - Expects Total Company 2025 Net Sales $3.57 Bln-$3.62 Bln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2557378794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557378794?lang=en_us&edition=fundamental","pubTime":"2025-08-06 18:36","pubTimestamp":1754476601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nFWN3TY16I:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NDOI"],"gpt_icon":0},{"id":"2557378777","title":"Mallinckrodt Plc - Well Positioned to Move Forward With Par Health Spin-off in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2557378777","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557378777?lang=en_us&edition=fundamental","pubTime":"2025-08-06 18:36","pubTimestamp":1754476601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nFWN3TY16I:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NDOI"],"gpt_icon":0},{"id":"2557378751","title":"Mallinckrodt Plc - Legacy Endo Q2 Revenues of $447.8 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2557378751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557378751?lang=en_us&edition=fundamental","pubTime":"2025-08-06 18:36","pubTimestamp":1754476601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nFWN3TY16I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NDOI"],"gpt_icon":0},{"id":"2553781207","title":"Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2553781207","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553781207?lang=en_us&edition=fundamental","pubTime":"2025-07-24 19:30","pubTimestamp":1753356635,"startTime":"0","endTime":"0","summary":"Endo Inc. Announces Phase 3 Clinical Trial for Nonsurgical Treatment of Plantar Fibromatosis at American Podiatric Medical Association Meeting. Endo Inc. has announced that it will present three research presentations related to plantar fibromatosis  and plantar fasciitis  at the upcoming American Podiatric Medical Association Annual Meeting, scheduled from July 24-27, 2025. These presentations will include findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum  for patients with PFA and PFI, as well as a retrospective analysis on insights from patients with PFI. CCH is not yet approved for treating PFI or PFA, and Endo is currently enrolling patients for a pivotal Phase 3 study for PFI.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL8sYHHZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDOI","BK4007"],"gpt_icon":0},{"id":"2553474874","title":"Endo Inc. to Release Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2553474874","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553474874?lang=en_us&edition=fundamental","pubTime":"2025-07-21 20:24","pubTimestamp":1753100697,"startTime":"0","endTime":"0","summary":"Endo Inc. will report its second quarter 2025 financial results on August 6, 2025, before market open. A conference call to present the results will be held on the same day at 8:00 a.m. ET. Results will be released through the Investor Relations section of the Company's website. The audio webcast may be accessed through the following URL: investor.endo.com.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire  on July 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDL6VghcS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NDOI"],"gpt_icon":0},{"id":"2552864994","title":"Irish High Court Approves Mallinckrodt and Endo Inc. Merger, Expected to Close in Early August","url":"https://stock-news.laohu8.com/highlight/detail?id=2552864994","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552864994?lang=en_us&edition=fundamental","pubTime":"2025-07-17 19:43","pubTimestamp":1752752627,"startTime":"0","endTime":"0","summary":"Mallinckrodt plc has announced that the Irish High Court has granted the necessary ruling to proceed with its merger with Endo, Inc. This development follows shareholder approval from both companies and represents the final substantive legal requirement for the transaction. The merger, expected to close in early August, will create a global therapeutics leader with Mallinckrodt's Dublin headquarters serving as the combined company's global base. Siggi Olafsson, CEO of Mallinckrodt, who will lead the new entity, emphasized the opportunity to accelerate value creation for stakeholders and enhance patient care. After the merger, the companies plan to merge their generic pharmaceuticals businesses and Endo's sterile injectables business, with a possible future separation subject to board approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL9ZNG17:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDOI","BK4007"],"gpt_icon":0},{"id":"2546322601","title":"Endo Inc. Conducted Annual Shareholder Meeting in Malvern","url":"https://stock-news.laohu8.com/highlight/detail?id=2546322601","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546322601?lang=en_us&edition=fundamental","pubTime":"2025-06-26 05:15","pubTimestamp":1750886144,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDLb3y24X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDOI","BK4007"],"gpt_icon":0},{"id":"2544903683","title":"Endo Is Maintained at Buy by BWS Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2544903683","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544903683?lang=en_us&edition=fundamental","pubTime":"2025-06-18 22:03","pubTimestamp":1750255380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NDOI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 18, 2025 10:03 ET (14:03 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDOI"],"gpt_icon":0},{"id":"2544967879","title":"Endo Inc. Completes Sale of International Pharmaceuticals Business to Knight Therapeutics for Up to $105 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2544967879","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544967879?lang=en_us&edition=fundamental","pubTime":"2025-06-17 20:31","pubTimestamp":1750163493,"startTime":"0","endTime":"0","summary":"Endo Inc. has announced the completion of its divestiture of the International Pharmaceuticals business, primarily operated through Paladin Pharma Inc. in Canada, to Knight Therapeutics Inc. The deal, previously announced, has now been finalized with a total cash consideration of up to approximately $105 million. This includes about $79 million paid at closing and an additional $11 million related to certain permitted holdbacks. Up to $15 million in future payments are also possible, contingent upon meeting specific milestones. The company announced the completion of this transaction on June 17, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL8JMnSb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Endo Inc. Completes Sale of International Pharmaceuticals Business to Knight Therapeutics for Up to $105 Million","news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NDOI"],"gpt_icon":0},{"id":"2543063556","title":"Press Release: Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader","url":"https://stock-news.laohu8.com/highlight/detail?id=2543063556","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543063556?lang=en_us&edition=fundamental","pubTime":"2025-06-13 23:04","pubTimestamp":1749827040,"startTime":"0","endTime":"0","summary":"Mallinckrodt to Apply to Irish High Court for Approval of Scheme of Arrangement. DUBLIN and MALVERN, Pa., June 13, 2025 /PRNewswire/ -- Mallinckrodt plc  and Endo, Inc.   today announced that their respective shareholders have provided the necessary shareholder approvals for the companies to combine in a stock and cash transaction that will create a global, scaled, diversified pharmaceuticals leader.With the necessary shareholder approval for the Mallinckrodt scheme of arrangement having been obtained, Mallinckrodt will now apply to the Irish High Court to confirm the scheme of arrangement. The timing of the court hearing and the decision to approve the scheme are subject to the High Court's discretion. Subject to having the sanction hearing in July and to satisfaction of the remaining closing conditions, Mallinckrodt and Endo are targeting completing the merger in the weeks following the sanction hearing.Mallinckrodt's headquarters in Dublin, Ireland, will serve as the combined compan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NDOI"],"gpt_icon":0},{"id":"2542554333","title":"BRIEF-Mallinckrodt, Endo Announce Planned Leadership Team For Merged Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2542554333","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542554333?lang=en_us&edition=fundamental","pubTime":"2025-06-09 22:06","pubTimestamp":1749477962,"startTime":"0","endTime":"0","summary":"BRIEF-Mallinckrodt, Endo Announce Planned Leadership Team For Merged CompanyJune 9 (Reuters) - Endo Inc NDOI.PK:MALLINCKRODT, ENDO ANNOUNCE PLANNED LEADERSHIP TEAM FOR MERGED COMPANYENDO INC - GENERIC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nFWN3SA0AF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDOI","BK4007"],"gpt_icon":0},{"id":"2542138401","title":"Press Release: Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2542138401","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542138401?lang=en_us&edition=fundamental","pubTime":"2025-06-09 20:30","pubTimestamp":1749472200,"startTime":"0","endTime":"0","summary":"Experienced and Highly Capable Senior Executives to Lead both the Branded Specialty Pharmaceutical and Generics & Sterile Injectables Businesses. DUBLIN and MALVERN, Pa., June 9, 2025 /PRNewswire/ -- Mallinckrodt plc  and Endo, Inc.   today announced the future executive team that will drive the creation of global, scaled, diversified therapeutics leaders in both the branded specialty pharmaceuticals and the generics and sterile injectables  businesses.As announced on March 13, 2025, the proposed merger of Mallinckrodt and Endo envisions creating both a branded specialty pharmaceuticals company and, later, separating the generic pharmaceuticals businesses of the two companies along with Endo's sterile injectable operations, which is currently intended to be implemented through a spin-off of the separated businesses in an independent entity. The merger remains on course to be completed in the second half of this year, subject to approval by shareholders of both companies and customary c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1543694498.USD","LU2041044095.USD","NDOI","LU1721428933.USD","LU2413666699.HKD","IE00BN0W2T93.GBP","BK4588","LU2413666426.HKD","LU2092937221.SGD","A","BK4567","BK4007","IE00BN0W2V16.EUR","BK4121","BK4120","BK4201","TISI","LU1165135440.EUR","BK4585","E","LU2089279066.USD","LU0347712357.USD","IE00BN0W2W23.USD","LU2229751404.USD"],"gpt_icon":0},{"id":"2535180821","title":"Endo Inc. Announces Launch of FDA-Approved ADRENALIN® 8 mg/250 mL Premixed Bag, Expanding Ready-to-Use Epinephrine Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2535180821","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535180821?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:36","pubTimestamp":1747341419,"startTime":"0","endTime":"0","summary":"Endo Inc. has announced the launch of its new ADRENALIN  8 mg/250 mL premixed bag, which is the first FDA-approved and currently the only commercially available manufacturer-prepared epinephrine premixed IV bag. The product, which will begin shipping the week of May 19, 2025, aims to support healthcare providers by reducing complexity and streamlining operations in hospitals through its ready-to-use format. Endo Inc. also plans to offer additional concentrations in the future, expanding their TruDelivery portfolio. No grant or funding from multiple organizations was mentioned in this announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endo Inc. published the original content used to generate this news brief via PR Newswire  on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL3ktHsg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NDOI"],"gpt_icon":0},{"id":"2535727260","title":"Press Release: Mallinckrodt and Endo Announce Significant Progress in Proposed Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2535727260","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535727260?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:00","pubTimestamp":1747137600,"startTime":"0","endTime":"0","summary":"S-4 Registration Statement Effective; HSR Waiting Period Expired. Irish High Court Approves Convening of Shareholder Meetings. DUBLIN and MALVERN, Pa., May 13, 2025 /PRNewswire/ -- Mallinckrodt plc  and Endo, Inc.   today reported significant progress toward their proposed merger to create a global, scaled, diversified therapeutics leader.Mallinckrodt's registration statement on Form S-4, which includes a joint proxy statement for the special meetings of Mallinckrodt and Endo to consider and vote on the proposed transaction, became effective as of Thursday, May 8, 2025. In addition, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired yesterday.Mallinckrodt has received permission from the Irish High Court to schedule the special meetings of its shareholders for June 13, 2025. Mallinckrodt's headquarters are in Dublin, Ireland, which will serve as the combined company's global headquarters following the close, presently expected in the se","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1165135440.EUR","BK4121","LU2413666699.HKD","BK4201","BK4567","BK4007","IE00BN0W2W23.USD","LU2089279066.USD","LU1721428933.USD","A","BK4588","LU0347712357.USD","LU2092937221.SGD","NDOI","LU1543694498.USD","BK4585","PRGS","LU2413666426.HKD","LU2041044095.USD","LU2065732104.USD","LU2229751404.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","E","BK4097"],"gpt_icon":0},{"id":"2534761592","title":"Endo Is Maintained at Buy by BWS Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2534761592","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534761592?lang=en_us&edition=fundamental","pubTime":"2025-05-12 21:51","pubTimestamp":1747057860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NDOI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2025 09:51 ET (13:51 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDOI"],"gpt_icon":0},{"id":"2533983121","title":"Press Release: Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2533983121","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533983121?lang=en_us&edition=fundamental","pubTime":"2025-05-07 19:00","pubTimestamp":1746615600,"startTime":"0","endTime":"0","summary":"-- XIAFLEX revenues grew 7% compared to first-quarter 2024. -- The Company reaffirms 2025 revenue guidance of $1,775 to $1,860 million. and adjusted EBITDA guidance of $620 to $650 million. -- Combination with Mallinckrodt expected to close in second half of 2025. MALVERN, Pa., May 7, 2025 /PRNewswire/ --- Endo, Inc.   today reported financial results for the first quarter ended March 31, 2025.\"As we advance Endo's transformation with two major transactions announced in March, the Company remains focused on executing our growth drivers, as evidenced by strong XIAFLEX performance in our Branded Pharmaceuticals business and the advancement of our Sterile Injectables pipeline,\" said Scott Hirsch, Endo's Interim CEO. \"As a result of our first-quarter results, which met internal expectations across all segments, we are reaffirming our full-year 2025 earnings guidance.\".   Endo acquired substantially all of the assets of Endo International plc.  on April 23, 2024, as contemplated by EIP's pl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4007","BK4022","R","NDOI"],"gpt_icon":0},{"id":"2525079698","title":"BRIEF-Endo To Report First Quarter 2025 Financial Results On May 7, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525079698","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525079698?lang=en_us&edition=fundamental","pubTime":"2025-04-08 04:30","pubTimestamp":1744057849,"startTime":"0","endTime":"0","summary":"BRIEF-Endo To Report First Quarter 2025 Financial Results On May 7, 2025Endo Inc NDOI.PK:ENDO TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON MAY 7, 2025Source text: ID:nPre4CFspaFurther company coverage: NDOI.PK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nTUA7T6PJC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NDOI"],"gpt_icon":0},{"id":"2525049674","title":"Endo Initiated at Buy by BWS Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2525049674","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525049674?lang=en_us&edition=fundamental","pubTime":"2025-04-07 21:48","pubTimestamp":1744033680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NDOI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2025 09:48 ET (13:48 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDOI","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}